PubMed · 16219562
The source did not provide an abstract. Follow the original record for more information.
Explore connections, maps & timelines
Jane E Barker. 2005. T time.. https://pubmed.ncbi.nlm.nih.gov/16219562/
Cite the original work for its findings. Save a collection to share your selection of sources.
KEEP EXPLORING
BACKGROUND: Despite decreases in overall mortality following bone marrow transplantation (BMT), a number of complications such as neurotoxicity have been described and often associated with immunosuppressive agents. The syndrome of reversible posterior leukoencephalopathy has been described in patients receiving cyclosporin and FK-506. We report here a subset of children who developed a syndrome of previously undescribed irreversible leukoencephalopathy following allogeneic BMT. PATIENTS AND METHODS: Between 1996 and 2002, 138 pediatric patients received an allogeneic BMT at Lucile Salter Packard Children's Hospital at Stanford. Six cases of irreversible leukoencephalopathy were observed. Cases were defined as children who exhibited progressive and continued, severe neurologic deterioration lasting greater than 2 weeks and consistent with non-localizing, central nervous system abnormalities. Medical records and magnetic resonance images (MRIs) were reviewed. RESULTS: Median age of the affected patients at BMT was 7.8 years. All six received cyclosporine, and [corrected] one had elevated drug levels. Encephalopathy occurred at a median of 53 days (range 14-77) following BMT. Symptoms at onset of leukoenceophalopathy included confusion and altered mental status, sluggish pupillary responses, abnormal movements, and seizures. Two patients died during their neurologic decline. Four patients remain alive with persistent encephalopathy. MRI showed abnormalities in all patients including periventricular or subcortical white matter involvement in all, and basal ganglia lesions in three. CONCLUSIONS: We report a syndrome of irreversible neurologic deficits and cerebral white matter abnormalities following allogeneic BMT, yet not associated with elevated cyclosporin levels. A precise mechanism for this syndrome is lacking and warrants further consideration.
In the competing-risks setting, to test the effect of a covariate on the probability of one particular cause of failure, the Fine and Gray model for the subdistribution hazard can be used. However, sometimes, competing risks data cannot be considered as independent because of a clustered design, for instance in registry cohorts or multicentre clinical trials. Frailty models have been shown useful to analyse such clustered data in a classical survival setting, where only one risk acts on the population. Inclusion of random effects in the subdistribution hazard has not been assessed yet. In this work, we propose a frailty model for the subdistribution hazard. This allows first to assess the heterogeneity across clusters, then to incorporate such an effect when testing the effect of a covariate of interest. Based on simulation study, the effect of the presence of heterogeneity on testing for covariate effects was studied. Finally, the model was illustrated on a data set from a registry cohort of patients with acute myeloid leukaemia who underwent bone marrow transplantation.
Explore the source record for details and available documents.